This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Beta Alethine in Treating Patients With Myeloma

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2002 by National Cancer Institute (NCI).
Recruitment status was:  Active, not recruiting
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: November 6, 2000
Last updated: December 17, 2013
Last verified: September 2002

RATIONALE: Biological therapies such as beta alethine use different ways to stimulate the immune system and stop cancer cells from growing.

PURPOSE: Phase I/II trial to study the effectiveness of beta alethine in treating patients who have myeloma.

Condition Intervention Phase
Multiple Myeloma and Plasma Cell Neoplasm Precancerous Condition Drug: beta alethine Phase 1 Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With Myeloma

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Study Start Date: August 2000
Detailed Description:


  • Determine the antitumor effects of low-dose beta alethine in patients with myeloma or progressive monoclonal gammopathy of undetermined significance.
  • Determine the effects of this regimen on anemia, performance status, pain, and delayed-type hypersensitivity (immune response) in these patients.
  • Determine the safety of this regimen in these patients.

OUTLINE: This is a multicenter study.

Patients receive beta alethine subcutaneously every 2 weeks for 6 doses. At day 85, patients may receive an additional 12-week course of therapy in the absence of disease progression or unacceptable toxicity. Patients with an apparent complete response receive additional courses.

Patients are followed for 2 weeks.

PROJECTED ACCRUAL: A total of 13-37 patients will be accrued for this study.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically proven myeloma

    • Multiple myeloma
    • Indolent myeloma with slowly progressive bone pathology
    • Smoldering myeloma with no bone pathology but a progressive increase in M-protein
    • Solitary myeloma OR
  • Diagnosis of evolving monoclonal gammopathy of undetermined significance with increasing M-protein or decreasing hemoglobin level
  • Measurable M-protein or Bence Jones protein
  • Indolent disease not requiring therapy allowed
  • No clinical signs or evidence of active brain involvement or leptomeningeal disease



  • 18 and over

Performance status:

  • Karnofsky 50-100%

Life expectancy:

  • At least 4 months


  • See Disease Characteristics
  • Neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3
  • Hemoglobin at least 10 g/dL


  • Bilirubin less than 2.0 mg/dL
  • Transaminases no greater than 2.5 times upper limit of normal


  • Creatinine no greater than 2.0 mg/dL
  • Creatinine clearance at least 60 mL/min


  • No acute changes on electrocardiogram
  • No uncontrolled angina, heart failure, or arrhythmia


  • Adequate nutritional status (total protein at least 60.0 g/L, albumin at least 35 g/L)
  • HIV negative
  • No AIDS
  • No active bacterial infection (e.g., abscess) or with fistula
  • No history of alcoholism, drug addiction, or psychotic disorders that would preclude study
  • No other nonmalignant disease that would preclude study
  • Not pregnant or nursing
  • Fertile patients must use effective contraception


Biologic therapy:

  • At least 4 weeks since prior immunotherapy or cytokines


  • At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas, mitomycin, or high-dose carboplatin)

Endocrine therapy:

  • No concurrent corticosteroids


  • No prior radiotherapy to greater than 25% of bone marrow


  • Recovered from any prior surgery
  • No prior solid organ transplantation


  • No other concurrent investigational agent
  • No concurrent immunosuppressive agents
  • No concurrent anti-inflammatory agents, including aspirin or over-the-counter or prescription nonsteroidal anti-inflammatory drugs
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00006466

United States, Georgia
Emory Clinic
Atlanta, Georgia, United States, 30322
United States, Maryland
Victory Over Cancer
Rockville, Maryland, United States, 20852
United States, New York
St. Vincents Comprehensive Cancer Center
New York, New York, United States, 10011
Sponsors and Collaborators
LifeTime Pharmaceuticals
Study Chair: Suzin Mayerson, PhD LifeTime Pharmaceuticals
  More Information Identifier: NCT00006466     History of Changes
Other Study ID Numbers: CDR0000068280
Study First Received: November 6, 2000
Last Updated: December 17, 2013

Keywords provided by National Cancer Institute (NCI):
monoclonal gammopathy of undetermined significance
isolated plasmacytoma of bone
extramedullary plasmacytoma
refractory multiple myeloma
stage I multiple myeloma
stage II multiple myeloma
stage III multiple myeloma

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Precancerous Conditions
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Cystine Depleting Agents
Molecular Mechanisms of Pharmacological Action processed this record on August 17, 2017